Steven Lin

Trials

Studies that name Steven Lin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:19 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07843537 · MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study

  M.D. Anderson Cancer Center · not yet recruiting · Thoracic Cancer · principal investigator
• Ph2
  NCT07597070 · Universal Immunization to Fortify Immunotherapy Efficacy and Response

  University of Florida · recruiting · Stage 4 NSCLC · principal investigator
• Ph1
  NCT06414902 · 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

  M.D. Anderson Cancer Center · recruiting · Esophageal Cancer · principal investigator
• Ph2
  NCT05632809 · REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

  M.D. Anderson Cancer Center · recruiting · Lung Cancer · principal investigator
• N/A
  NCT05394766 · Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension

  Stanford University · completed · Hypertension · principal investigator
• Ph1
  NCT02389751 · Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

  M.D. Anderson Cancer Center · completed · Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus, Malignant Neoplasm of the Thoracic Esophagus · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 100 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Role of genomic and microenvironment factors in conferring acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma
  U54CA274220 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2026 · $306,002 awarded in 2026
  Same name and institution; not confirmed by an ID
• Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches
  U01CA216468 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2021 · $596,334 awarded in 2021
  Same name and institution; not confirmed by an ID
• Mitigating High Grade Radiation-Induced Lymphopenia through Pretreatment Autologous Lymphocyte Infusion
  R21CA240881 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2021 · $176,175 awarded in 2021
  Same name and institution; not confirmed by an ID
• Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy
  R21CA241001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2020 · $174,000 awarded in 2020
  Same name and institution; not confirmed by an ID
• DOES OLANZAPINE INHIBIT THE SECRETORY RESPONSE TO INSULIN RESISTANCE?
  M01RR000070 · NCRR · STANFORD UNIVERSITY · fiscal years 2008 · $21,503 awarded in 2008
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT02389751